Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7099399 | 0.90 | MAPT (0.50) | MAPTKDM4EMAPK1L3MBTL1MEN1 | |
| SCHEMBL6234634 | 0.88 | MMP13 (0.58) | MAPTKDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL7190819 | 0.88 | MAPT (0.49) | MAPTKDM4EMAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7629640 | 0.88 | MAPT (0.49) | MAPTKDM4EMAPK1MEN1KMT2A | |
| SCHEMBL7190815 | 0.88 | MAPT (0.49) | MAPTKDM4EMAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7099302 | 0.87 | MAPT (0.53) | MAPTKDM4EMAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7104549 | 0.87 | ALDH1A1 (0.53) | MAPTKDM4EMAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7629654 | 0.87 | MAPT (0.48) | MAPTKDM4EMAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7629636 | 0.87 | MAPT (0.48) | MAPTKDM4EMAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL7627970 | 0.87 | MAPT (0.52) | MAPTKDM4EMAPK1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | claimed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | claimed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | MAPT 4823/4885KDM4E 1784/4885MAPK1 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.